Introduction
============

*Staphylococcus aureus* is an opportunistic pathogen causing a wide range of hospital- and community-acquired infections with high morbidity ([@B5]; [@B4]) Diseases caused by the Gram-positive bacterium range from skin infections to life-threatening illnesses, such as septicemia, pneumonia, endocarditis, meningitis, and catheter-related infections due to biofilm formation ([@B4]; [@B13]; [@B2]). *S. aureus* is also a leading cause of staphylococcal food poisoning because it can produce a wide variety of toxins including staphylococcal enterotoxins and staphylococcal-like proteins ([@B21]; [@B6]). The disease caused by *S. aureus* is a worldwide public health issue ([@B16]; [@B4]), and the situation is exacerbated by the emergence of drug-resistant strains, particularly the methicillin-resistant *S. aureus* (MRSA) ([@B43]; [@B11]). Some success has been achieved in the discovery and development of various drugs for the treatment of infections caused by antibiotic-resistant pathogens ([@B37]; [@B45]; [@B1]).

Plant-derived antimicrobial agents have received much attention due to their effectiveness against drug-resistant strains, and diverse antimicrobial activities including suppression of virulence factors, antibiofilm activity, anti-persister activity and inhibition of efflux pumps in pathogens ([@B9]; [@B26]; [@B8]; [@B19]). Thousands of phytochemicals have been reported as antibacterial compounds and belong to different classes, such as alkaloids, terpenoids, polyphenols, tannins, and phenanthrenes. Among of them, phenanthrenes are a relatively uncommon class of aromatic metabolites in the plant kingdom, and are mainly found in the Orchidaceae and Juncaceae ([@B20]; [@B41]). As typical phytoalexins of these plants, phenanthrenes have been shown to possess antimicrobial activities against various pathogens including drug-resistant strains ([@B20]; [@B40]; [@B44]; [@B31]; [@B41]). Correspondingly, some phenanthrene-containing plants have been used in traditional medicine for the treatment of infectious diseases ([@B38]; [@B27], [@B28]).

*Bletilla striata* (Reichb. f.), a precious medicinal plant, has been used in traditional medicine for the treatment of pneumorrhagia and pneumonophthisis ([@B38]). Early investigations on the chemical constituents of plant revealed the presence of mono phenanthrenes, dimeric phenanthrenes, and their derivatives ([@B31]; [@B12]). The contents of mono phenanthrenes have been found to be higher than those of dimeric phenanthrenes in *B. striata*, although dimers generally have significantly stronger antibacterial activity than the monomers. During a recently screening program of antimicrobial phytochemicals, we found four new 9′,10′-dihydro-biphenanthrenes from the medicinal plant ([@B31]). One of them, 4,7,4′-trimethoxy-9′,10′-dihydro(1,1′-biphenanthrene)-2,2′,7′-triol, named as blestriacin (**Figure [1](#F1){ref-type="fig"}**), exhibits significant antibacterial activity against all tested Gram-positive bacteria including MRSA with MICs of 2--4 μg/mL.

![Structure of blestriacin.](fmicb-09-01593-g001){#F1}

Although the antimicrobial activity of phenanthrenes is well documented, their mode of action has not been reported. In this work, we use blestriacin as a tool compound to investigate the antibacterial mechanism of phenanthrenes through a combination of approaches, including minimum inhibitory concentration (MIC)/minimum bactericidal concentration **(**MBC) determination, time-killing assay, growth kinetics analysis, membrane potential estimation, membrane integrity measurement, and genome sequencing analysis.

Materials and Methods {#s1}
=====================

Bacterial Strains and Materials
-------------------------------

*Staphylococcus aureus* ATCC 29213, *S. aureus* ATCC 43300, and *Enterococcus faecalis* ATCC 29212 were purchased from the American Type Culture Collection. *Bacillus subtilis* 168 was a gift from Mei-Ya Li (Zhejiang Chinese Medical University, Hangzhou, China). Clinical isolates were obtained from patients at the Shaoxing Central Hospital, Shaoxing, China. All bacterial strains used for the activity assay were grown routinely at 37°C on Mueller--Hinton (MH) agar/broth.

Blestriacin was isolated and purified from the fibrous roots of *B. striata* according to the method described previously ([@B31]). The purity of the compound was determined with HPLC and found to be \>95%. The rhizomes of *B. striata* were collected from Tuankou Town, Zhejiang Province, China, and authenticated by Professor ZS Ding. A voucher specimen was deposited in Zhejiang Chinese Medical University with specimen number BS-2012-I. Nisin was purchased from Sigma-Aldrich (St. Louis, MO, United States), and other antibiotics were obtained from Shanghai Yuanye Bio-Technology Co. (Shanghai, China). Propidium iodide (PI) and bis-(1,3-dibutylbarbituric acid) trimethine oxonol \[DiBAC~4~(3)\] were purchased from BD Biosciences (San Diego, CA, United States) and Enzo Life Sciences (Farmingdale, NY, United States), respectively.

Determination of MIC and MBC
----------------------------

The MIC of the antimicrobial agents in 96-well microtiter plates was determined by using the broth microdilution method ([@B12]). Bacteria were seeded at 5 × 10^5^ cells per well in a 96-well plate containing MH broth with varying concentrations of each test sample. Vancomycin, erythromycin, and oxacillin were used as positive controls. Blestriacin was dissolved in dimethyl sulfoxide (DMSO). Sterile MH broth containing 5% DMSO was used as negative control. MBC was determined by subculturing 0.1 mL from each well showing no visible sign of growth in the MH agar. The MIC was defined as the lowest concentration of drug which inhibited visible growth after incubation at 37°C for 20 h, and the MBC was defined as the lowest compound concentration resulting in a ≥3-log reduction in the number of CFU after incubation for 24 h at 37°C ([@B12]).

Time-Kill Assay
---------------

The time-kill kinetics of blestriacin was determined for four *S. aureus* strains as previously reported ([@B12]). Briefly, the antimicrobial agent was added to a logarithmic-phase broth culture of approximately 10^6^ CFU/mL to yield concentrations of 1× MIC, 2× MIC, and 4× MIC. The same volume of DMSO was added to the control tube. The culture was incubated at 37°C with shaking for 24 h. One hundred microliter aliquots were removed from each test tube after 0, 0.5, 1, 3, 6, and 24 h of incubation, and serially diluted (1:10) with cold saline. The appropriate dilutions (100 μL) were then spotted on MH agar plates (5 μL per spot), and viable bacteria were quantitated after 24 h of incubation at 37°C. Results were obtained from three independent experiments presented as the average ± standard deviation (SD).

Growth Kinetics Analysis
------------------------

Overnight cultures of *Bacillus subtillis 168* were grown in MH broth at 37°C to an OD600 of 0.3. The bacteria were then diluted one-fold in pre-warmed MH broth containing 4× the MIC of the indicated antimicrobial agents. Bacterial growth was monitored by measuring optical density at 600 nm (OD600nm) with a microplate spectrophotometer (Multiscan MK3, Thermo Labsystems).

Determination of Membrane Potential and Integrity
-------------------------------------------------

The effects of blestriacin on the potential of bacterial membrane was tested by flow cytometry with a fluorescent probe DiBAC~4~(3) ([@B10]). The cells of *B. subtilis* 168 and *S. aureus* 29213 were grown in MH broth to an OD600 of 0.5 and diluted twice with sterilized saline water. After incubation with an antimicrobial agent at 4× MIC for specified time at 37°C, the cells were harvested by centrifugation at 8000 rpm for 5 min and washed twice with sterile saline. The resulting pellets were resuspended in normal saline to approximately 10^6^ CFU/mL. The cells were then stained for 30 min at 37°C with 60 μL of DIBAC~4~(3). Fluorescence was measure with an Accuri C6 flow cytometer (BD Biosciences) with excitation and emission wavelengths of 485 and 520 nm, respectively.

Membrane integrity assays were performed in the same manner as the method described above, except that the fluorescent dye PI was added to a final concentration of 30 μM instead of DiBAC~4~(3). Flow cytometric data were collected with the Accuri C6 flow cytometer with excitation at 490 nm and emission collected at 635 nm. Nisin was used as a positive control for membrane damage and vancomycin as a negative control. The reported results were obtained from three independent cultures.

Scanning Electron Microscopy (SEM)
----------------------------------

For the electron microscopy analysis, overnight cultures of bacteria grown in MH broth was collected by centrifugation (6000 rpm for 5 min at 4°C) and washed three times with sterilized saline water. Bacterial cells present in the suspension containing 10^8^ CFU/mL were incubated with or without blestriacin (32 μg/mL) for 3 h. After incubation, the bacterial suspension was again centrifuged and washed three times with sterilized saline water. A thin smear of bacterial suspension was prepared on a glass slide, air-dried, and fixed with 2.5% glutaraldehyde in phosphate-buffered saline (PBS, 0.1 mol/L, pH7.0) at 4°C overnight. The sample was washed three times with PBS and post-fixed in 1% osmium tetroxide for 20 min, followed by dehydration in gradually increased concentration of ethanol ranging from 50 to 100% (10 min in each stage). The samples were then serially dehydrated in 50, 75, 90, and 100% tert-butanol solutions, followed by vacuum freeze drying for 1 h with a t-BuOH freeze dryer (VFD-21S, Vacuum Device Inc., Japan). The dried cells were coated with gold using a sputter coater (Hitachi E-1010, Japan), and observed under a scanning electron microscope (Hitachi SU8000, Japan).

Isolation and Analysis of Spontaneous Resistant Mutants
-------------------------------------------------------

An inoculum of 3 × 10^10^ CFU/mL of *S. aureus* was spread onto MH plates containing different concentrations of blestriacin. All plates were incubated at 37°C overnight and examined after 48 h. Mutational frequency was determined as previously described ([@B18]). Individual colonies resistant to blestriacin were isolated and purified from MH agar containing the same blestriacin concentration. The MICs of mutants were confirmed by the broth microdilution method as described above.

Whole Genome Sequencing and Assembly
------------------------------------

Wild type *S. aureus* 43300 (Sa01) together with its drug-resistant mutants Sa02 and Sa03 were subjected to genomic DNA isolation with a ZR Fungal/Bacterial Genomic DNA Extraction Kit (Zymo Research Corp., Orange, CA, United States). Genome sequencing was performed by Sangon Biotech (Shanghai, China). An Illumina MiSeq platform with 2 × 150-bp reads was used for the sequencing. The reads were trimmed, quality-filtered and then assembled by using SPAdes software ([@B7]). BWA/SAMtools ([@B23]; [@B22]) were used for alignment of raw reads and single nucleotide polymorphism (SNP) detection. SNP presented in both mutant strains was confirmed by PCR and Sanger dideoxy-terminator sequencing. Mutations were compared with a reference genome of *S. aureus* MRSA252 (genome NC_002952.2). Sequence similarities were investigated by using the BLAST server at the National Center for Biotechnology Information (NCBI^[1](#fn01){ref-type="fn"}^) site. This Whole Genome Shotgun projects have been deposited at DDBJ/ENA/GenBank under the accessions: Sa01 QAJW00000000; Sa02 QAJX00000000; Sa03 QAJY00000000. The version described in this paper is version QAJW 01000000, QAJX01000000, QAJY01000000, respectively.

Results
=======

Clinical Isolates of *S. aureus* Are Highly Susceptible to Blestriacin
----------------------------------------------------------------------

Blestriacin exhibits significantly anti-Gram-positive bacterial activity against *S. aureus, Staphylococcus epidermidis, E. faecalis*, and *B. subtilis* ([@B31]). To further evaluate the effect of blestriacin against *S. aureus*, we determined the MICs of the 13 clinical isolates consisting of methicillin-resistant (MRSA) and -sensitive (MSSA) *S. aureus* using a microbroth dilution method. Consistent with previous study ([@B31]), blestriacin was active against most of the tested clinical isolates with the MICs ranging from 2 to 4 μg/mL, whether the isolate is a methicillin-resistant strain (MICs of Oxacillin \> 4 μg/mL) (**Table [1](#T1){ref-type="table"}**).

###### 

MICs of blestriacin against clinical isolates of *Staphylococcus aureus.*

  Indicator strain         MIC (μg/mL)                
  ------------------------ ------------- ----- ------ -------
  *S. aureus* 3211         2             1     \>4    \>4
  *S. aureus* 3304         2             0.5   \>4    \>4
  *S. aureus* 0001         8             1     \>4    \>4
  *S. aureus* 0002         2             1     \>4    \>4
  *S. aureus* 0003         4             1     ≤0.5   ≤0.25
  *S. aureus* 0004         4             2     \>4    \>4
  *S. aureus* 0005         2             1     ≤0.5   ≤0.25
  *S. aureus* 0006         2             1     ≤0.5   ≤0.25
  *S. aureus* 0007         2             1     ≤0.5   ≤0.25
  *S. aureus* 0008         2             1     \>4    \>4
  *S. aureus* 0009         2             1     ≤0.5   ≤0.25
  *S. aureus* 0010         2             1     ≤0.5   ≤0.25
  *S. aureus* 0011         2             1     ≤0.5   ≤0.25
  *S. aureus* ATCC 29213   2             1     0.5    0.125

Blestriacin Is a Bactericidal Agent
-----------------------------------

Minimum bactericidal concentration test showed that blestriacin exerted bactericidal effect upon *S. aureus* strains with the MBC/MIC ratios of 1--2 (**Table [2](#T2){ref-type="table"}**). Interestingly, blestriacin had a MBC/MIC ratio of 1 against *E. faecalis* ATCC 29212, while vancomycin yielded MBC/MIC ratios of \>4 against the same strain. To further examine the bactericidal activities of blestriacin against *S. aureus*, we performed killing experiments against two standard strains and two clinical isolates. As shown in **Figure [2](#F2){ref-type="fig"}**, blestriacin was bactericidal in a dose-dependent manner. No living cell was detected at 24 h for all tested strains treated with 4× the MIC of blestriacin, which is consistent with the bactericidal behavior revealed by the MBC/MIC analysis described above.

###### 

MBCs of blestriacin against *Staphylococcus aureus* and *Enterococcus faecalis.*

  Strain and compound             MIC (μg/mL)   MBC (μg/mL)   MBC/MIC
  ------------------------------- ------------- ------------- ---------
  *S. aureus* ATCC 29213 (MSSA)                               
       Blestriacin                2             4             2
       Vancomycin                 1             2             2
  *S. aureus* ATCC 43300 (MRSA)                               
       Blestriacin                2             2             1
       Vancomycin                 2             2             1
  *S. aureus* 3211 (MRSA)                                     
       Blestriacin                2             2             1
       Vancomycin                 1             2             2
  *S. aureus* 3304 (MRSA)                                     
       Blestriacin                2             2             1
       Vancomycin                 2             2             1
  *E. faecalis* ATCC 29212                                    
       Blestriacin                2             2             1
       Vancomycin                 2             \>8           \>4

![Time-kill curves for *Staphylococcus aureus* treated with different concentrations of blestriacin. The curves are viable cell concentrations plotted against time. Open circles, nondrug control; closed squares, 1× MIC of blestriacin; closed triangles, 2× MIC of blestriacin; closed circles, 4× MIC of blestriacin. MIC, minimum inhibitory concentration. Data represent the mean ± SD (*n* = 3).](fmicb-09-01593-g002){#F2}

Blestriacin Disrupts Membrane Potential and Integrity
-----------------------------------------------------

To preliminarily investigate the possible mechanism of antimicrobial action of blestriacin, we determined the growth kinetics of *B. subtilis* 168 exposed to blestriacin or various antibiotics with known mechanisms of action ([@B35]). The results (**Figure [3A](#F3){ref-type="fig"}**) demonstrated that blestriacin exhibited kinetic behavior similar to rapidly lytic membrane-active agents (such as polymyxin and nisin) but not to cell wall--interfering agents (such as vancomycin, oxacillin) or antibiotics with transcription (rifampicin), or protein synthesis (kanamycin, erythromycin) as its primary target. Consistently with this, the bacteria killing of blestriacin for *B. subtilis* 168 was rapid at the concentration of 4× MIC, and no living cell was detected within 120 min (**Figure [3B](#F3){ref-type="fig"}**). Thus, the effect of blestriacin on membrane potential and integrity was investigated.

![Effect of blestriacin on *Bacillus subtilis* 168. **(A)** Growth kinetics of *B. subtilis* 168 exposed to blestriacin or various antibiotics with known mechanisms of action. Four times the minimal inhibitory concentration (MIC) of the respective compounds were used. **(B)** Killing kinetics of blestriacin against *B. subtilis* 168. Open circles, nondrug control; closed squares, 1× MIC of blestriacin; closed triangles, 2× MIC of blestriacin; closed circles, 4× MIC of blestriacin. The MIC of blestriacin against *B. subtilis* 168 is 2 μg/mL. All experiments were performed in triplicate, and analysis data are presented as the mean ± SD.](fmicb-09-01593-g003){#F3}

The ability of blestriacin to induce membrane depolarization was evaluated by using the fluorescent dye DiBAC~4~(3), which can enter depolarized membranes and exhibit increased green fluorescence due to its binding to lipid-rich intracellular components ([@B3]). As expected, the addition of blestriacin or nisin to *B. subtilis* 168 suspensions caused a drastic in fluorescence, indicating that the agent was capable of disrupting the membrane potential of *B. subtilis* (**Figure [4A](#F4){ref-type="fig"}**). By contrast, the negative-control vancomycin did not alter the membrane potential. The effect of blestriacin on the membrane integrity of *B. subtilis* 168 was monitored using a PI fluorescent probe, which is an indicator of disturbance of plasmatic membrane integrity. Fluorescence measurement showed that blestriacin caused membrane damage of *B. subtilis* 168, which was evident by a great increase in the red fluorescence of cells.

![The effect of blestriacin on membrane potential and integrity of *B. subtilis* 168 **(A)** and *S. aureus* ATCC 29213 **(B)**. Representative data from three independent cultures of both strains are shown following exposure to antimicrobial agents at 4× MIC for 2 h, except the incubation time of *S. aureus* ATCC 29213 with blestriacin was 3 h. Vancomycin was used as a negative control and nisin was used as a positive control. Con, no-drug treated control; Van, vancomycin (4 μg/mL); Nis, nisin (20 μg/mL). BP03, blestriacin.](fmicb-09-01593-g004){#F4}

The capability of blestriacin to disrupt membrane potential and integrity of *S. aureus* 29213 was also determined. As shown in **Figure [4B](#F4){ref-type="fig"}**, when *S. aureus* was treated with blestriacin for 3 h, a drastic increase in fluorescence of DiBAC~4~(3) and PI were both observed compared with the untreated cultures. Interestingly, incubation of *S. aureus* 29213 with 4× MIC of blestriacin for 2 h leads to a weak increase in fluorescence, while incubation of *B. subtilis* 168 with the same concentration of blestriacin for only 0.5 h leads to a great increase in fluorescence of both dyes (data not shown). These results indicated that the membrane of *B. subtilis* 168 is more vulnerable than that of *S. aureus* 29213 to blestriacin.

To investigate the effects of blestriacin on cell morphology of bacteria, scanning electron microscopic analysis were carried out. As shown in **Figure [5A](#F5){ref-type="fig"}**, untreated *S. aureus* had smooth and intact morphology. In contrast, numerous lysed cells accompanied by cellular debris were observed in the bacteria treated with blestriacin (**Figure [5B](#F5){ref-type="fig"}**). Similarly, the antimicrobial agent also induced dramatic morphological changes and structure disruption of *B. subtillus* cells (**Figures [5C,D](#F5){ref-type="fig"}**).

![Scanning electron microscopic analysis of bacteria. **(A)** and **(C)**: Represent cells of *S. aureus* ATCC 29213 and *B. subtilis* 168 without treatment at magnifications of 10000×, respectively. **(B)** and **(D)**: Cells of *S. aureus* ATCC 29213 and *B. subtilis* 168 incubated with 32 μg/mL blestriacin for 3 h at magnifications of 10000×, respectively.](fmicb-09-01593-g005){#F5}

Blestriacin Kills *S. aureus* With a Low Spontaneous Resistance Mutation Frequency
----------------------------------------------------------------------------------

To determine the spontaneous resistance mutation frequency of *S. aureus* against blestriacin, we plated *S. aureus* ATCC 29213 at 10^10^ CFU onto MH agar containing 4×, and 8× MICs of blestriacin. No mutant of strain 29213 resistant to blestriacin was observed even when plating on media was conducted with a low dose (4× MIC) of the compound. Then we carried out a study with *S. aureus* ATCC 43300. Blestriacin -resistant *S. aureus* were obtained only by growing the strain on MH agar plates containing blestriacin at 4× MIC. The resistance frequency was determined to be about 2 × 10^-9^. Broth MIC determination of blestriacin -resistant *S. aureus* strains showed twofold increase compared to wild-type bacteria. Interestingly, blestriacin -resistant mutants also exhibited reduced (two-fold) susceptibility to nisin, but showed no changes in sensitivity toward vancomycin and kanamycin.

Blestriacin Resistance in *S. aureus* Is Associated With Mutations in Multi-Genes
---------------------------------------------------------------------------------

To gain insight into the genetic bases of blestriacin resistance in *S. aureus* ATCC 43300, we isolated and sequenced the genomic DNAs of two independently selected blestriacin resistant strains (Sa02 and Sa03) and parent strain. No significantly change in the growth rates of the two mutants were observed, except the twofold increase in the MIC compared to wild-type *S. aureus*. Whole-genome sequencing revealed six common single-nucleotide polymorphisms in the two mutants, including five nonsynonymous substitutions and one synonymous substitution in coding regions of the genomes (**Table [3](#T3){ref-type="table"}**).

###### 

Nucleotide mutations presented in both mutant strains (Sa02 and Sa03) of *S. aureus* ATCC 43300 compared to the wide-type strain.

  SNP   Nucleotide change   Predicted amino change   *S. aureus* MRSA252 Locus tag   Predicted gene product
  ----- ------------------- ------------------------ ------------------------------- ------------------------------------------------------------
  1     T→G                 N207K                    SAR0206                         Maltose ABC transporter substrate-binding protein ([@B30])
  2     A→G                 T111A                    SAR0210                         gfo/Idh/MocA family oxidoreductase ([@B17])
  3     A→T                 K225I                    SAR2028                         Aspartate aminotransferase ([@B29])
  4     T→A                 R48S                     SAR2257                         Putative multidrug efflux transporter
  5     C→A                 A30S                     SAR2480                         Transcriptional regulator ([@B25])
  6     A→T                 V301V                    SAR2589                         MFS transporter

The Sa02 and Sa03 strains harbored the substitution Arg48Ser in a locus tag, SAR2257, which is annotated as a putative transport protein involved in multidrug resistance ([@B14]). The locus SAR2257 contains a frameshift after codon 114 in *S. aureus* MRSA252 reference strain but not in the parent and mutant strains of *S. aureu*s ATCC 43300. Four additional nonsynonymous SNPs were identified in open reading frames predicted to encode maltose ABC transporter, oxidoreductase, aspartate aminotransferase and transcriptional regulator. Maltose ABC transporter and oxidoreductase seem to be related to the transport and metabolism of sugars, while aspartate aminotransferase and transcriptional regulator are probably related to the metabolism of amino acids and nitrate regulation, respectively.

Discussion
==========

In this study, the antibacterial properties of blestriacin, a dihydro-biphenanthrene isolated from the fibrous roots of *B. striata* were investigated. Blestriacin exhibited potent bactericidal activity against *S. aureus*, including MRSA. Several other phenanthrenes from *B. striata* and other plants have also been reported to possess antimicrobial activity against a wide range of pathogens ([@B39]; [@B20]; [@B31]). However, most of their MICs exceeded 10 μg/mL. On the basis of the MIC values, which are below 10 μg/mL for the natural compound against *S. aureus* and other Gram-positive bacteria, blestriacin is regarded as an effective antibacterial agent and deserves more attention ([@B33]; [@B32]).

Although phenanthrenes have been studied as antimicrobial agents since the 1980s ([@B39]), the mechanism of the action of these compounds has not been investigated. Growth kinetic measurements of *B. subtilis* 168 exposed to various antibiotics showed that blestriacin exhibited kinetic behavior similar to polymyxin and nisin, suggesting blestriacin is a membrane-damaging agent. To test whether blestriacin is a cytoplasmic membrane disruptive agent, we investigated the effect of the compound on membrane potential and integrity. As expected, blestriacin disrupted the bacterial membrane integrity of *B. subtilis* and *S. aureus*, and this was accompanied with the dissipation of membrane potential in two test strains. Consistent with the observation that the bactericidal speed of blestriacin to *B. subtilis* was faster than that of *S. aureus*, the membrane of *B. subtilis* is more vulnerable than that of *S. aureus* against blestriacin. The correlation between the time dependence of antibiotic activity and the effects on membrane integrity further confirmed that blestriacin kills bacterial cells by damaging their cytoplasmic membranes. Consistent with these results, SEM images showed that both bacteria exposed to blestriacin had severely damaged morphology (**Figure [5](#F5){ref-type="fig"}**).

Pathogens can evolve to acquire resistance to nearly all antibiotics, which is widely associated with treatment failure. The spontaneous mutation rate of bacteria to an antibiotic is closely related to the mechanism of action of a drug used. It is reported that the development of resistance is less frequent for several membrane-active agents than for other antibiotics ([@B36]; [@B15]). The spontaneous mutation frequency of *S. aureus* to blestriacin was determined to be 2 × 10^-9^ or less, which is consistent with the finding that blestriacin is a membrane-targeted agent.

Genetic characterization of *in vitro*-derived mutants resistant to an antibacterial agent can provide information about the mechanism of antibiotic resistance as well as the mode of action of this active compound. Whole-genome sequencing of blestriacin -resistant mutants (Sa02 and Sa03) of *S. aureus* and their parent revealed nonsynonymous single nucleotide variants in five open reading frames. One of these genes encoded a putative transporter (SAR2257). Further inspection revealed that the putative protein was similar to the QacA/EmrB multidrug resistance efflux pumps, which were response regulators of two-component systems. The pump QacA conferred resistance to quaternar ammonium cations from *S. aureus* ([@B34]), and EmrB protects *Escherchia coil* from uncouplers ([@B24]). A unique feature of *emr* consisting of *emrA* and *emrB* is that it seems to confer resistance only to fairly hydrophobic compounds. As blestriacin is a natural phenanthrene with extremely low water solubility, we hypothesized that the putative transporter (SAR2257) is likely to participate in blestriacin efflux from bacterial membranes. However, how the putative transporter participates in blestriacin resistance requires further investigation.

Four additional nonsynonymous SNPs were identified in both mutant strains. Although the role of these mutations is less clear and the predicted functions of these genes seem to be not directly associated with drug resistance, their role in the development of blestriacin resistance in *S. aureus* cannot be ruled out. These gene mutations may help bacteria to better adapt to stress through changes in cell metabolism and transport that optimize the global cellular response to antimicrobial agent exposures. It was recently reported that daptomycin resistance in *E. faecalis* was associated with mutations in eight genes ([@B42]).

Conclusion
==========

Overall, our findings demonstrate that blestriacin, a natural phenanthrene, is a unique bactericidal antibiotic. It has a membrane-damaging activity and low propensity to select or induce resistance in *S. aureus*. The development of blestriacin resistance in *S. aureus* involves mutations in multi-genes, which is unlike those agents act upon one target and for which a single point mutation can confer significant resistance. All these observations are consistent with the finding that blestriacin acts as a membrane-damaging antibiotic.
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